Evidence map›Paper›PMID 34063511›Full record

ArticleCancers2021

A Rare Variant in

Lisa Anne Cannon-Albright, Craig Carl Teerlink, Jeff Stevens, Franklin W Huang, Csilla Sipeky, Johanna Schleutker, Rolando Hernandez, Julio Facelli, Neeraj Agarwal, Donald L Trump

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. A Rare Variant inCancers · 2023
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Lisa Anne Cannon-AlbrightGenetic Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT 84112, USA.ORCID 0000-0003-2602-3668
Craig Carl TeerlinkGenetic Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT 84112, USA.
Jeff StevensGenetic Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT 84112, USA.
Franklin W HuangDivision of Hematology/Oncology, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, Bakar Computational Health Sciences Institute, Institute for Human Genetics, University of California, San Francisco, CA 94143, USA.
Csilla SipekyInstitute of Biomedicine and FICAN West Cancer Centre, University of Turku, Turku University Hospital, 20521 Turku, Finland.ORCID 0000-0002-8853-4722
Johanna SchleutkerInstitute of Biomedicine and FICAN West Cancer Centre, University of Turku, Turku University Hospital, 20521 Turku, Finland.ORCID 0000-0002-1863-0305
Rolando HernandezDepartment of Biomedical Informatics, University of Utah School of Medicine, Salt Lake City, UT 84108, USA.
Julio FacelliDepartment of Biomedical Informatics, University of Utah School of Medicine, Salt Lake City, UT 84108, USA.ORCID 0000-0003-1449-477X
Neeraj AgarwalHuntsman Cancer Institute, University of Utah, Salt Lake City, UT 84108, USA.ORCID 0000-0003-1076-0428
Donald L TrumpInova Schar Cancer Institute, Inova Health System, 8081 Innovation Park Drive, Fairfax, VA 22031, USA.
University of Utah · USUniversity of Turku · FIInova Health System · USUniversity of California, San Francisco · US

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI KATHARINE S ULLMAN · 1986 to 2026
$72.6M
Utah Center for Clinical and Translational ScienceUL1TR002538 · NCATS · UNIVERSITY OF UTAH · PI HESS, RACHEL, MAJERSIK, JENNIFER JUHL · 2018 to 2022
$26.0M
CDC HHS NU58DP0063200-01NCATS NIH HHS 1ULTR002538NCATS NIH HHS UL1 TR002538NCI NIH HHS HHSN261201800016INCI NIH HHS P30CA42014NIH HHS 1S19OD02164401A1
6 · The paper itself

Abstract

Pairs of related bladder cancer cases who belong to pedigrees with an excess of bladder cancer were sequenced to identify rare, shared variants as candidate predisposition variants. Candidate variants were tested for association with bladder cancer risk. A validated variant was assayed for segregation to other related cancer cases, and the predicted protein structure of this variant was analyzed. This study of affected bladder cancer relative pairs from high-risk pedigrees identified 152 bladder cancer predisposition candidate variants. One variant in

Indexed as

bladder cancerERFhigh-risk pedigreepredispositionprostate cancerUPDB

Identifiers

PMID34063511
PMCPMC8156789
OpenAlexW3161365741

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.